

Tuberculosis profile: China

Population 2021: 1 426 million

Estimates of TB burden*, 2021

	Number	(Rate per 100 000 population)
Total TB incidence	780 000 (665 000-905 000)	55 (47-63)
HIV-positive TB incidence	10 000 (8 800-12 000)	0.73 (0.62-0.85)
MDR/RR-TB incidence**	33 000 (27 000-39 000)	2.3 (1.9-2.8)
HIV-negative TB mortality	30 000 (27 000-33 000)	2.1 (1.9-2.3)
HIV-positive TB mortality	2 100 (1 600-2 700)	0.15 (0.11-0.19)

Estimated proportion of TB cases with MDR/RR-TB*, 2021

New cases	3.4% (3.3-3.5)
Previously treated cases	19% (19-20)

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2021	75% (65-88)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2021	4% (3-5)

TB case notifications, 2021

Total new and relapse	585 340
- % tested with rapid diagnostics at time of diagnosis	57%
- % with known HIV status	70%
- % pulmonary	95%
- % bacteriologically confirmed [^]	58%
- % children aged 0-14 years	1%
- % women (aged ≥15 years)	31%
- % men (aged ≥15 years)	68%
Total cases notified	593 743

TB/HIV care in new and relapse TB patients, 2021

	Number	(%)
Patients with known HIV status who are HIV-positive	5 429	1.3%
- on antiretroviral therapy	4 711	87%

Drug-resistant TB care**, 2021

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases [^]	80%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases [^]	92%
Laboratory-confirmed cases - MDR/RR-TB ^{^^}	16 826
Patients started on treatment - MDR/RR-TB ^{^^^}	12 846
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^{^^}	60
Patients started on treatment - pre-XDR-TB or XDR-TB ^{^^^}	43
MDR/RR-TB cases tested for resistance to any fluoroquinolone	188

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2020	95%	608 737
Previously treated cases, excluding relapse, registered in 2020	89%	7 947
HIV-positive TB cases registered in 2020	86%	5 784
MDR/RR-TB cases started on second-line treatment in 2019	53%	13 525
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2019		


TB preventive treatment, 2021

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	


Funding for TB

Funding for TB, 2021 (US\$ millions)	792
- % domestic funding	100%
- % international funding	0.018%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence (Rate per 100 000 population per year)




HIV-negative TB mortality (Rate per 100 000 population per year)




Incidence, Notified cases by age group and sex, 2021 (Number)



Cases attributable to five risk factors, 2021 (Number)



Funding for TB (US\$ millions)



* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.
** RR is TB resistant to rifampicin (R), MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone
^ Calculated for pulmonary cases only
^^ Includes cases with unknown previous TB treatment history
^^^ Includes patients diagnosed before 2021 and patients who were not laboratory-confirmed

Generated 2022-11-28 by the World Health Organization (<https://www.who.int/teams/global-tuberculosis-programme/data>)